DYSMENORRHEA, ADENOMYOSIS, ENDOMETRIOSIS, TUMOR PROCESS: CAUSATION
https://doi.org/10.21518/2079-701X-2017-11-186-188
Abstract
The article focuses on the identification of causal relationships between dysmenorrhea, endometrioid and tumor processes. Studies have shown that dysmenorrhea, apart from a decline in the quality of life, can be the cause of development of a number of serious health disturbances, including endometriosis, adenomyosis and even tumoral diseases. Non-steroidal anti-inflammatory drugs are not only the effective means of therapy for dysmenorrhea patients, but also a pathogenetically reasonable approach to prevent the outbreak of the disease.
About the Authors
A. L. Unanyan
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Unanyan MD, Prof.
I. S. Sidorova
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Academician of RAS, MD, Prof.
N. A. Nikitina
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
PhD in medicine
Y. V. Chushkov
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
PhD in medicine
T. D. Guriev
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
PhD in medicine, Prof.
A. D. Nikonets
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
D. V. Baburin
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus-revisited. Am J Obstet Gynecol, 1972, 112: 583-593.
2. Lee NC, Dicker RC, Rubin GL, Ory HW. Confirmation of the preoperative diagnoses for hysterectomy. Am J Obstet Gynecol, 1984, 150: 283–287.
3. Barrier BF, Malinowski MJ, Dick EJ Jr, Hubbard GB, Bates GW. Adenomyosis in the baboon is associated with primary infertility. Fertil Steril, 2004, 82: 1091–1094.
4. Ryan GL, Stolpen A, Van Voorhis BJ. An unusual cause of adolescent dysmenorrhea. Obstetrics and gynecology, 2006, 108(4): 1017-1022.
5. Dietrich JE. An update on adenomyosis in the adolescent. Curr Opin Obstet Gynecol, 2010, 22: 388–392.
6. Pontis A, D’Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol, 2016 Jul 5: 1-5.
7. Zhou C, Zhang T, Liu F, Zhou J, Ni X, Huo R, Shi Z. The differential expression of mRNAs and long noncoding RNAs between ectopic and eutopic endometria provides new insights into adenomyosis. Mol Biosyst, 2016 Feb, 12(2): 362-70.
8. Tong X, Li Z, Wu Y, Fu X, Zhang Y, Fan H. COMT 158G/A and CYP1B1 432C/G polymorphisms increase the risk of endometriosis and adenomyosis: a meta-analysis. Eur J Obstet Gynecol Reprod Biol, 2014 Aug, 179: 17-21.
9. Wang Y, Qu Y, Song W. Genetic variation in COX-2-1195 and the risk of endometriosis andadenomyosis. Clin Exp Obstet Gynecol, 2015, 42(2): 168-72.
10. Herndon CN, Aghajanova L, Bayalan S, Erikson D, Barragan F, Goldfien G, Vo KC, Hawkins S, Giudice LC. Global Transcriptome Abnormalities of the Eutopic Endometrium From Women With Adenomyosis. Reprod Sci, 2016 May 27.
11. Benedetto C. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol, 1989, 3(1): 71-94.
12. Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update, 1998, 4(4): 312-322.
13. Brosens I, Derwig I, Brosens J, Fusi L, Benagiano G, Pijnenborg R The enigmatic uterine junctional zone: the missing link between reproductive disorders and major obstetrical disorders? Hum Reprod, 2010 Mar, 25(3): 569-74.
14. Ibrahim MG, Chiantera V, Frangini S, Younes S, Köhler C, Taube ET, Plendl J, Mechsner S. Ultramicro-trauma in the endometrial-myometrial junctional zone and pale cell migration in adenomyosis. Fertil Steril, 2015 Dec, 104(6): 1475-83.e1-3.
15. Leyendecker G, Bilgicyildirim A, Inacker M, Stalf T, Huppert P, Mall G, Böttcher B, Wildt L. Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study. Arch Gynecol Obstet, 2015 Apr, 291(4): 917-32.
16. Nigam S, Benedetto C, Zonca M, Leo-Rossberg I, Lübbert H, Hammerstein J. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids, 1991, 4(3): 137-41.
17. Zelenay S, Reis E Sousa C. Reducing prostaglandin E2 production to raise cancer immunogenicity. Oncoimmunology, 2016 Jan 4, 5(5): e1123370.
18. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN.Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994 Oct, 107(4): 1183-8.
19. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med, 1993 Nov, 122(5): 518-23.
20. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol, 2004 Mar, 11(3): 328-39.
21. Wallace AE, Sales KJ, Catalano RD, Anderson RA, Williams AR, Wilson MR, Schwarze J, Wang H, Rossi AG, Jabbour HN. Prostaglandin F2alpha-Fprostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Res, 2009 Jul 15, 69(14): 5726-33.
22. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia, 2000 NovDec, 2(6): 483-90.
23. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrialadenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer, 2001 Sep 28, 85(7): 1023-31.
24. Wallace AE, Gibson DA, Saunders PT, Jabbour HN. Inflammatory events in endometrial adenocarcinoma. J Endocrinol, 2010 Aug, 206(2): 141-57
25. Babic A, Cramer DW, Titus LJ, Tworoger SS, Terry KL. Menstrual pain and epithelial ovarian cancer risk. Cancer Causes Control, 2014 Dec, 25(12): 1725-31.
26. Kvaskoff M, Mu F, Terry KL, Harris HR, Poole EM, Farland L, Missmer SA. / Endometriosis: a highrisk population for major chronic diseases? Hum Reprod Update, 2015 Jul-Aug, 21(4): 500-16. doi: 10.1093/humupd/dmv013. Epub 2015 Mar 11.
27. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol, 2015 Sep, 16(9): 1061-70. Epub 2015 Aug 4.
28. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Lancet, 2008 Jan 26, 371(9609): 303-14.
29. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B,Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a casecontrol study. Lancet Oncol, 2007 Jan, 8(1): 26-34.
30. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update, 2009 Sep-Oct, 15(5): 489-98.
31. Инструкция к применению препарата Амелотекс http: //www.sotex.ru/production/catalog/detail.php?ELEMENT_ID=4268.
Review
For citations:
Unanyan AL, Sidorova IS, Nikitina NA, Chushkov YV, Guriev TD, Nikonets AD, Baburin DV. DYSMENORRHEA, ADENOMYOSIS, ENDOMETRIOSIS, TUMOR PROCESS: CAUSATION. Meditsinskiy sovet = Medical Council. 2017;(11):186-188. (In Russ.) https://doi.org/10.21518/2079-701X-2017-11-186-188
Views:
997
Email this article 